trastuzumab

You have access
A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results
JUNJI KAWADA, DAISUKE SAKAI, YUTAKA KIMURA, MOTOHIRO HIRAO, KAZUHIRO NISHIKAWA, NAOTOSHI SUGIMOTO, YOSHIO OKA, SHUNJI ENDO, YUTAKA ISOZAKI, JIN MATSUYAMA, RYOHEI KAWABATA, TOMONO KAWASE, KAZUMASA FUJITANI, YUKINORI KUROKAWA, HISATO KAWAKAMI, TOSHIO SHIMOKAWA, TAROH SATOH and Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)

Anticancer Research March 2025, 45 (3) 1077-1085; DOI: https://doi.org/10.21873/anticanres.17495
Open Access
Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer
FABIAN HUBER, ISIS WOLF, JONAS STORZ, SUSANNE SCHULTZE-SEEMANN, SUSAN LAUW, LUKAS KLEMENZ, ARKADIUSZ MIERNIK, CHRISTIAN GRATZKE, REINHARD BRÜCKNER and PHILIPP WOLF

Anticancer Research May 2024, 44 (5) 1837-1844; DOI: https://doi.org/10.21873/anticanres.16985
Open Access
Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH
JUNYA KONDO, SHIGEFUMI YOSHINO, MICHIHISA IIDA, SHIGERU TAKEDA, CHIYO NAKASHIMA, YUSAKU WATANABE, MITSUO NISHIYAMA, YUKIO TOKUMITSU, YOSHITARO SHINDO, TAKU NISHIMURA, NOBUAKI SUZUKI, YOSHINOBU HOSHII, HIROSHI ITOH and HIROAKI NAGANO

Anticancer Research February 2024, 44 (2) 621-630; DOI: https://doi.org/10.21873/anticanres.16851
Open Access
Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor
SANT P. CHAWLA, OLGA OLEVSKY, GEETA IYENGAR, DON A. BRIGHAM, NADEZHDA OMELCHENKO, SONU THOMAS, KUSHAL SURYAMOHAN, LELAND FOSHAG, FREDERICK L. HALL and ERLINDA M. GORDON

Anticancer Research June 2023, 43 (6) 2383-2391; DOI: https://doi.org/10.21873/anticanres.16406
You have access
Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis
TAKAAKI ARIGAMI, DAISUKE MATSUSHITA, KEISHI OKUBO, KEN SASAKI, YUSUKE TSURUDA, YOSHIAKI KITA, SHINICHIRO MORI, SHIGEHIRO YANAGITA, YOSHIKAZU UENOSONO, HIROSHI KURAHARA and TAKAO OHTSUKA

Anticancer Research June 2021, 41 (6) 3099-3107; DOI: https://doi.org/10.21873/anticanres.15094
You have access
Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer
GEORGIOS RIGAKOS, EVANGELIA RAZIS, GEORGIA-ANGELIKI KOLIOU, GEORGIOS OIKONOMOPOULOS, ELEFTHERIA TSOLAKI, JEFF SPERINDE, SOFIA CHRISAFI, GEORGE ZARKAVELIS, ELISSAVET PAZARLI, ANNA BATISTATOU, HELEN P. KOUREA, PAVLOS PAPAKOSTAS, DIMITRIOS BAFALOUKOS, NATALIA I. ASIMAKOPOULOU, ELENI RES, ATHANASIOS KOTSAKIS, DIMITRIOS PECTASIDES, ANGELOS KOUTRAS, CHRISTOS CHRISTODOULOU and GEORGE FOUNTZILAS

Anticancer Research April 2021, 41 (4) 1793-1802; DOI: https://doi.org/10.21873/anticanres.14945
You have access
Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer
LARS CHRISTIAN HANKER, FRANK FÖRSTER, JAN SCHRÖDER, ANDREA GRAFE, THOMAS HITSCHOLD, TOBIAS HESSE, CLAUS RICHARD LATTRICH and ACHIM RODY

Anticancer Research July 2020, 40 (7) 3973-3981; DOI: https://doi.org/10.21873/anticanres.14390
You have access
Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab
MASAYA TAKAHASHI, KATSUYUKI TAKAHASHI, SAYA MATSUMOTO, TSUTOMU TAKASHIMA, YUKA ASANO, TAMAMI MORISAKI, SHINICHIRO KASHIWAGI, SATORU NODA, NAOYOSHI ONODA, MASAICHI OHIRA and KATSUYA NAGAYAMA

Anticancer Research July 2020, 40 (7) 4047-4051; DOI: https://doi.org/10.21873/anticanres.14401
You have access
Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice
MASAHIRO OKAMOTO, WAKAKO TAJIRI, HIROKI UEO, TAKANOBU MASUDA, HIDEKI IJICHI, CHINAMI KOGA, YOSHIAKI NAKAMURA, KENICHI TAGUCHI, SHINJI OHNO and ERIKO TOKUNAGA

Anticancer Research June 2020, 40 (6) 3315-3323; DOI: https://doi.org/10.21873/anticanres.14314
You have access
Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma
MASASHI TAKAHASHI, KAZUMASA FUKUDA, YOSHIRO SAIKAWA, RIEKO NAKAMURA, NORIHITO WADA, HIROFUMI KAWAKUBO, HIROYA TAKEUCHI and YUKO KITAGAWA

Anticancer Research April 2020, 40 (4) 1921-1930; DOI: https://doi.org/10.21873/anticanres.14147

Main menu

User menu

Search

trastuzumab

Pages